

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
26 June 2003 (26.06.2003)

PCT

(10) International Publication Number
WO 03/051375 A1

(51) International Patent Classification⁷: **A61K 31/7072**,
47/08, 47/10, 47/12

10, I-00040 Pomezia (RM) (IT). **MANZINI, Stefano**
[IT/IT]; Via Tito Speri, 10, I-00040 Pomezia (RM) (IT).

(21) International Application Number: PCT/EP02/13714

(74) Agents: **BANFI, Paolo** et al.; Bianchetti Bracco Minoja
S.r.l., Via Rossini, 8, I-20122 Milano (IT).

(22) International Filing Date: 4 December 2002 (04.12.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
101 62 593.6 19 December 2001 (19.12.2001) DE

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE,
SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,
VC, VN, YU, ZA, ZM, ZW.

(71) Applicants (*for all designated States except US*):
MENARINI RICERCHE S.P.A. [IT/IT]; Via Tito Speri,
10, I-00040 Pomezia (RM) (IT). **BERLIN-CHEMIE AG**
[DE/DE]; Glienicke Weg 125, 12489 Berlin (DE).

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK,
TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **SCHNITTKER,**
Christian [DE/DE]; Glienicke Weg 125, 12489 Berlin
(DE). **KEIPERT, Sigrid** [DE/DE]; Glienicke Weg
125, 12489 Berlin (DE). **GRÖGER, Karsten** [DE/DE];
Glienicke Weg 125, 12489 Berlin (DE). **SCHMITZ,**
Reinhard [DE/DE]; Glienicke Weg 125, 12489 Berlin
(DE). **MAGGI, Carlo, Alberto** [IT/IT]; Via Tito Speri,

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 03/051375 A1

(54) Title: STABILIZED BRIVUDINE TOPICAL FORMULATIONS

(57) Abstract: Topical formulations containing the virustatic agent brivudine and stabilizers useful to present its photodegradation are disclosed.

STABILIZED BRIVUDINE TOPICAL FORMULATIONS

The present invention relates to topical formulations containing the virustatic agent brivudine and stabilizers useful to prevent its photodegradation.

State of the art

5 Brivudine ((E) -5-(2-bromovinyl)-2'-deoxyuridine) is an antiviral agent which is very effective against the varicella-zoster virus (VZV) and against the herpes simplex virus type 1 (HSV-1). Against VZV and HSV-1, brivudine is consistently more active than other known virustatic drugs such as aciclovir (ACV) and penciclovir (PCV). However, brivudine light-instability strongly
10 limits its use in therapy. In particular, the UV light causes the isomerization of brivudine to Z-BVDU, as well as the formation of other decomposition products, with consequent decrease of clinical effectiveness. Photostabilization of brivudine is greatly recommended especially for dosage forms which are likely to undergo prolonged light exposure, such as dermal
15 formulations.

Different approaches have been proposed to stabilize drugs from photodegradation.

US6136332 describes a non-aqueous dermatological/pharmaceutical composition for treating afflicted lips which is resistance to transfer or
20 migration upon topical application to human skin. The resistance is the result of the combination of at least one volatile oil and at least one phenylated silicone oil. The invention also includes therapeutical agents having a degree of antiviral activity. Furthermore it includes organic and inorganic sunscreens agents but does not give any hint on how selecting the suitable
25 ones. However, the invention does not resolve the problem of an effective photostabilization of the virustatic agent brivudine.

EP 0147811 describes the photostabilization of molsidomine by the addition of flavonoid derivatives, such as troxerutine, that exert an antioxidative effect.

US 5290774 describes the stabilization of light sensitive drugs by the use of polyhydric alcohols and boric acid, which form a complex in aqueous solution.

DE 3136282 proposes to protect light-unstable drugs using substances with a similar absorption profile. The protective effect is supposed to depend on the similarity between the absorption spectra of the stabilizer and of the drug, that is, the larger is the overlapping between the two absorption spectra, the better is the photo-stabilization. According to DE3136282, the ICH (International Conference on Harmonisation) guideline CPMP/ICH/279/95 was followed to determine brivudine degradation. Several substances, including pharmaceutical excipients, colorants or photostable drugs were tested in admixture with brivudine. However, most of the tested food-colourants, including Quinoline yellow or Vanillin, did not satisfactorily stabilize brivudine.

Description of the invention

It has now been found that certain substances with an absorption spectrum different from that of brivudine, provide a satisfactory photostabilization of the latter.

Best results were obtained with colourants of the azo-type, like Cochineal Red A (E 124; Ponceau 4R; 7-Hydroxy-8-(4-sulfonato-1-naphthylazo)-naphthalin-1,3-disulfonic acid, trisodium salt; CAS: 2611-82-7), Tropaeolin 0 (2,4-dihydroxyazobenzol-4'-sulfonic acid sodium salt; CAS: 547-57-9), or Food red 9 (E 123; 3-Hydroxy-4-(4-sulfonato-1-naphthylazo)-naphthalin-2,7-disulfonic acid, Trisodium salt; CAS: 915-67-3). This group of compounds is structurally characterized by the presence of an azo group in

combination with two aromatic systems such as benzene, naphthalene, pyridine, pyrrole, thiophene, where the two aromatic systems may have up to four substituents selected from hydroxy, amino, sulfhydryl, methoxy, ethoxy, C1-C4-alkyl, carboxy, formyl, sulfonic or phosphonic acids and the
5 corresponding salts.

The spectrum of these azo-colourants is notably different from that of brivudine. Cochineal Red A, for example, shows an absorption maximum at 330 and 505 nm, while the absorption maximum for brivudine is at 250 nm and 290 nm. Cochineal Red A led to a more than threefold increased
10 photostabilization of brivudine. Food red 9 was found to protect brivudine from decomposition by more than 30% over the controls. The best recovery rates were obtained with Tropaeolin 0. When used in a concentration of 5%, nearly no degradation of brivudine was detectable in a 1% formulation. Tropaeolin 0 shows an absorption maximum at about 395 nm.

15 In addition, several UV-absorbers were tested as photostabilizers for brivudine.

No effects were observed with padimate O, phenylbenzimidazole sulfonic acid, Uvinul® T150, Uvinul® P25 or homosalate.

Surprisingly UV-absorbers having an o-hydroxy-benzophenone
20 structure, such as dioxybenzone, oxybenzone, 2,2',4,4'-tetrahydroxybenzophenone, 2,4-dihydroxy benzophenone, 2,2'-dihydroxy-4,4'-dimethoxybenzophenone-5,5'-disodium sulfonate, and sulisobenzene, were found to effectively stabilize brivudine formulations against UV-radiation. Although these absorbers have not an absorption profile similar to that of
25 brivudine – for example the absorption maximum of 2,2',4,4'-tetrahydroxybenzophenone is about 350 nm -, they induced a threefold increased brivudine recovery after irradiation, i.e. about 75% of the initial concentration, with respect to brivudine alone. Benzophenone derivatives

according to the invention include those compounds in which the aromatic rings forming the benzophenone moiety carry up to eight substituents selected from hydroxy-, amino, sulfhydryl-, methoxy-, ethoxy-, C1-C4-alkyl-, carboxy-, formyl-, sulfonic- and phosphonic acid and the corresponding salts. Included
5 are also the same compounds bearing at least one hydroxy group in ortho position to the keto group of benzophenone.

Besides the o-hydroxy-benzophenone derivatives and the azo-colourants, photostabilization of brivudine was also obtained with carotenoids, especially with beta-carotene. The latter, which shows nearly no absorbance in
10 the radiation range from 250 to 350nm, allows a remarkable photostabilization of brivudine. Carotenoids according to the invention refer to compounds having a tetraterpene structure with up to 12 conjugated double bonds selected from alpha-, beta-, gamma- and delta-carotene, lycopene, lutein, canthaxanthin, cryptoxanthin, rodoxanthin, zeaxanthin, crocetin, astaxanthin,
15 fucoxanthin and violaxanthin.

Substances of the group of antioxidants/ radical quenchers were tested for their stabilization properties. Substances like cystein or alpha-liponic acid did not show any effect of brivudine photostabilization.

Differently, the UV-absorbers avobenzene, octocrylene, methyl-
20 benzylidene-camphor, octyl-methoxy-cinnamate, diphenyl-propane 1,3-dione derivatives and cyano-diphenyl acrylic acid derivatives were found to stabilize brivudine, although to a lesser extent than the benzophenone derivatives or the azo colourants. Therefore they were not deemed to be preferred solutions of the present invention.

25 According to the invention, the group of diphenyl-propane 1,3-dione derivatives includes compounds in which the two aromatic rings present in the diphenyl-propane 1,3-dione moiety bear up to six substituents independently selected from hydroxy, sulfhydryl, methoxy, ethoxy, C1-C4-alkyl, carboxy,

formyl, sulfonic or phosphonic acid, and the corresponding salts, whereas cyano-diphenyl acrylic acid derivatives include those compounds in which the cyano-diphenyl acrylic acid moiety carries up to six substituents selected from hydroxy, sulfhydryl, methoxy, ethoxy, C1-C4-alkyl, carboxy, formyl, sulfonic
5 or phosphonic acid, and the corresponding salts.

Object of the present invention is therefore a topical formulation containing brivudine as the active principle and at least one of the photo-stabilizer above mentioned, together with pharmaceutically acceptable excipients, according to claim 1.

10 The group of compounds having a phenyl-azo-benzene or an o-hydroxy-benzophenone structure, as well as the carotenoids, are preferred. UV-absorbers, especially those of the o-hydroxy-benzophenone type, allow the preparation of colorless dermal formulations, which guarantee an effective photostabilization of the drug once applied onto the skin. The efficacy of
15 photostabilization can be further improved combining different o-hydroxy-benzophenone derivatives, UV-adsorbers, carotenoids and/or phenyl-azo-benzene derivatives. In fact, the hydrophilic/lipophilic balance of multicomponent formulations has been found to influence the effectiveness of photostabilization. For example, a combination of the hydrophilic and
20 lipophilic photostabilizers sulisobenzone and, respectively, oxybenzone in a O/W emulsion, provides a better brivudine-photostabilization than the same concentration of each stabilizer separately.

According to the invention, the photo-stabilizers can be used in a concentration of 0.1% to 10%, preferably from 0.5 to 5% w/w.

25 Preferred topical formulations are in the form of gels, emulsions, microemulsions, creams, ointments and lipsticks. Suitable methods for preparing the pharmaceutical compositions of the invention are known to anyone skilled in the art and are described, for example, in Remington's

Pharmaceutical Science, 17th ed., Mack Publishing Company, Easton, PA (1985). For some formulations viscosity increasing ingredients were used. These are known thickening agents as derivatives of cellulose, starch and fatty acid as well as aluminium stearate, cetearyl alcohol, silica, beeswax, cera alba, Carbomer, polyvinyl alcohol. In any case no phenyl-containing silicone oil was used in the present formulations.

Where the formulation has not adequate antimicrobial activity per se, or it is not preserved by a special manufacturing or container, antimicrobial preservatives may be added, particularly for formulations in multidose containers. The antimicrobial preservatives can be selected from the group of quaternary ammonium compounds, for instance cetrimonium chloride or benzalkonium chloride, derivatives of the p-hydroxybenzoic acid, such as methyl-4-hydroxybenzoate or propyl-4-hydroxybenzoate, derivatives of benzoic acid and sorbic acid. Other antimicrobial preservatives are chorhexidine, chloroxymethylbenzole, imidazolidiny urea, 2-bromo-2-nitro-1,3-propanediol, benzyl alcohole, phenoxyethylalcohol, phenylmercuric acetate.

The stabilized formulations of the invention are conveniently used in the topical treatment of VZV and HSV-1 infections.

Stability tests

Table 1: Stabilization of brivudine by different substances in a tenside gel (brivudine-/dye-/UV-absorber-concentration: 1% w/w); Irradiation with a xenon lamp according to ISO 10977, SUNTEST CPS+, Atlas Co.

Dye/ UV absorber	% recovery rate (mean, n=2 to 13)
no addition	26.1
Quinoline Yellow*	3.0
Tartrazine*	10.6
beta carotene	35.0
Food red 9**	56.2
Cochineal Red A **	77.6
Tropaeolin 0**	84.9
Sulisobenzon***	37.7
2,2',4,4'-tetrahydroxybenzophenon***	59.2
Dioxybenzone***	69.3

* negative examples (no photostabilizing effect in spite of similar absorption to brivudine)

**azo-colourant

10 ***benzophenon derivative

Table 2: Stabilization of brivudine solutions by different dyes or UV-absorbers in a microemulsion (brivudine-/ dye-/ UV-absorber-concentration: 1% w/w); Irradiation with a xenon lamp, 7200kJ/m² according to ISO 10977, SUNTEST CPS+, Atlas Co.; because of a special sample presentation (sealed quartz containers) the recovery rates in the microemulsion are generally higher than those obtained with the tensid gel or the O/W creams

Dye/ UV absorber	recovery rate in% (mean, n=3)
no addition	73.0
Food red 9 **	99.1
Cochineal Red A **	100.1
Sulisobenzzone***	88.1
Oxybenzone***	89.6
2,2',4,4'-tetrahydroxybenzophenon***	93.6
Dioxybenzone***	94.4

**azo-colourant

10 ***benzophenon derivative

15

20

Table 3: Photostabilization of brivudine by different UV-absorbers in **O/W-cream** (brivudine-concentration: 1% w/w; absorber-concentration 5% w/w); Irradiation with a xenon lamp, 7200kJ/m² according to ISO 10977, SUNTEST CPS+, Atlas Co.

5

UV absorber	recovery rate in % (mean, n=3)
no addition	14.3
Uvinul [®] P25*	0.3
Padimate O	17.2
Sulisobenzone***	37.2
Oxybenzone***	61.7
2,2',4,4'-tetrahydroxybenzophenon***	67.8
Dioxybenzone***	85.7

* negative examples (no photostabilizing effect)

*** benzophenon derivative

Table 4: Photostabilization of brivudine by different UV-absorbers in **O/W-cream** (brivudine-concentration: 2% w/w; absorber-concentration 5% w/w); Irradiation with a xenon lamp, 7200kJ/m² according to ISO 10977, SUNTEST CPS+, Atlas Co.

10

UV absorber	recovery rate in % (mean, n=3)
no addition	9.9
2.5% Sulisobenzone***/ 2.5% Uvinul [®] D50***	48.1
2.5% Sulisobenzone***/ 2.5% Oxybenzone***	78.3
2.5% Sulisobenzone***/ 2.5% Dioxybenzone***	83

***benzophenon derivative

The following examples illustrate the invention in greater detail.

EXAMPLES- Pharmaceutical compositions

The following microemulsions were prepared by mixing all ingredients at a temperature of 30°C for two hours:

Example 1.

5	brivudine	1%
	oxybenzone	4%
	isopropyl myristate	29.5%
	poloxamer 101	11.8%
	polysorbate 85	17.7%
10	silicon dioxide	10.7%
	water	q.s. ad 100%

An antimicrobial preservative can eventually be added.

Example 2

	brivudine	1 to 2.5%
15	dioxybenzone	0.5 to 2.5%
	isopropyl myristate	25 to 37%
	poloxamer 101	8 to 20%
	polysorbate 85	15 to 25%
	silica	5 to 12%
20	methyl-4-hydroxybenzoate	0.18%
	propyl-4-hydroxybenzoate	0.2%
	water	q.s. ad 100%

Example 3

	brivudine	1 to 2.5%
25	2,2',4,4'-tetrahydroxybenzophenone	0.5 to 5%
	isopropyl palmitate	25 to 37%
	poloxamer 101	8 to 20%
	PEG-(50)-sorbitol-hexaoleat	15 to 25%

benzalkonium chloride	0.05 to 0.1%
edetic acid	0.1%
water	q.s. ad 100%

Example 4

5	brivudine	1 to 2.5%
	oxybenzone	0.5 to 6%
	isopropyl myristate	25 to 37%
	poloxamer 101	8 to 20%
	polysorbate 85	15 to 25%
10	water	q.s. ad 100%

Example 5

	brivudine	1 to 2.5%
	sulisobenzene	0.5 to 2.5%
	isopropyl myristate	25 to 37%
15	poloxamer 122	8 to 20%
	PEG-(40)-sorbitol hexaoleate	15 to 25%
	sorbic acid	0.1 to 0.2%
	citric acid	q.s.
	water	q.s. ad 100%

20 Example 6

	brivudine	1 to 2.5%
	cochineal Red A	0.5 to 2.5
	isopropyl myristate	25 to 37%
	poloxamer 101	8 to 20%
25	PEG-(25)-Glycerin-Trioleate	15 to 25%

The following gel formulation was prepared by mixing the poloxamers and water at temperatures between 10°C to 20°C for 6 to 8 hours and then adding the remaining ingredients under intensive mixing:

Example 7

	brivudine	1 to 2%
	dioxybenzone	0.5 to 2.5%
	poloxamer 407	1 to 10%
5	poloxamer 188	10 to 40%
	water	q.s. ad 100%

Example 8

	brivudine	1 to 2%
	2,2',4,4'-tetrahydroxybenzophenone	0.5 to 5%
10	poloxamer 407	1 to 10%
	poloxamer 188	10 to 40%
	methyl-4-hydroxybenzoate	0.18%
	propyl-4-hydroxybenzoate	0.02%
	water	q.s. ad 100%

15 Example 9

	brivudine	1 to 2%
	sulisobenzone	0.5 to 5%
	sodium hydroxide	q.s.
	poloxamer 407	1 to 10%
20	poloxamer 188	10 to 40%
	chlorohexidine	0.05%
	water	q.s. ad 100%

Example 10

	brivudine	1 to 2%
25	cochineal red A	0.5 to 5%
	poloxamer 407	1 to 10%
	poloxamer 188	10 to 40%
	cetrimonium chloride	0.05 to 0.1%

water	q.s. ad 100%
-------	--------------

Example 11

	brivudine	1 to 2%
	beta carotene	0.1 to 2.5%
5	poloxamer 407	1 to 10%
	poloxamer 188	10 to 4%
	methyl-4-hydroxybenzoate	0.18%
	propyl-4-hydroxybenzoate	0.2%
	water	q.s. ad 100%

- 10 The following Carbomer gels are prepared by mixing all ingredients with exception of 1,2-propandiol and water. Afterwards the mixture is added to 1,2-propandiol. At least the water is added. This system is mixed until a clear gel is formed.

Example 12

15	brivudine	1 to 2.5%
	sulisobenzone	0.5 to 2.5%
	carbomer 940	1 to 2%
	tris(hydroxymethyl)aminomethane	1 to 3%
	1,2-propandiol	5 to 40%
20	citric acid	q.s.
	methyl-4-hydroxybenzoate	0.18%
	propyl-4-hydroxybenzoate	0.2%
	water	q.s. to 100%

Example 13

25	brivudine	1 to 2.5%
	cochineal red A	0.5 to 2.5%
	carbomer 940	1 to 2%
	tris(hydroxymethyl)aminomethane	1 to 3%

1,2-propandiol	5 to 40%
benzalkonium chloride	0.1%
edetic acid	0.1%
water	q.s. to 100%

5 Example 14

The following **O/W creams** were prepared by emulsification and homogenisation at 80°C, cooling down to 20°C to 30°C and adding the active ingredient under intensive mixing.

	brivudine	1 to 2.5%
10	sulisobenzone	0.5 to 2.5%
	oxybenzone	0.1 to 6%
	1,2-propandiol	10 to 20%
	potassium hydroxide	q.s.
	paraffin oil, subliquidum	15 to 30%
15	vasilinum album	15 to 27%
	polyoxyethylene-monostearate	2 to 5%
	cetostearyl alcohol	2 to 5%
	polydimethylsiloxane	0.01 to 0.5%
	imidazolidiny urea	0.6%
20	propyl-4-hydroxybenzoate	0.1 to 0.2%
	water	q.s. ad 100%

Example 15

The following ointment is prepared by melting and mixing the oily ingredients. Then the active ingredient and the UV-Absorber are added. The
25 ointment is cooled down to room temperature maintaining stirring and homogenising if necessary.

brivudine	1 to 2.5%
oxybenzone	0.5 to 6%

paraffin oil, perliquidum	2 to 10%
vasilinum album	q.s. ad 100%

The following **lipsticks** were prepared by melting and mixing the lip stick ingredients at about 70°C to 80°C. Then the active ingredient and the UV-Absorber are added. Subsequently the mixture is cast into lip stick container.

Example 16

brivudine	1 to 2.5%
dioxybenzone	0.5 to 2.5%
cochineal red A	0.1 to 1%
glycerine monostearate	6 to 10%
hydrogenated coco-glycerides	28 to 29%
caprylic/ capric triglyceride	38 to 39%
glycerine tricaprte	4 to 8%
cera alba	4 to 6%
hydrogenated palm oil	1 to 3%
vaselinum album	q.s. to 100%

Example 17

brivudine	1 to 2.5%
oxybenzone	0.5 to 6%
cochineal red A	0.1 to 1%
glycerine monostearate	12 to 20%
hydrogenated coco-glycerides	28 to 29%
caprylic/ capric triglyceride	28 to 39%
mixed ester of diglycerol with caprylic-/capric-/	
isostearic-/hydroxystearic- and adipic acid	13 to 34%
cera alba	q.s. to 100%

Description of the non-proprietary names used:

Substance	description
1,2-propandiol	Propylene Glycol (USP 24)
Carbomer 940	Carbomer 940 (USPNF19)
Carbomer 934 P	Carbomer 934 P (USPNF19)
Cera alba	White wax (USPNF19)
Cetostearyl alcohol	Cetostearyl alcohol (USPNF19)
Cochineal Red A	E 124; Ponceau 4R; 7-Hydroxy-8-(4-sulfonato-1-naphthylazo)-naphthalin-1,3-disulfonic acid, Trisodium salt; CAS: 2611-82-7
Dioxybenzone	Dioxybenzone (USP24)
Phenylbenzimidazole Sulfonic Acid	Phenylbenzimidazole Sulfonic Acid (USP24)
Padimate O	Padimate O (USP24)
Homosalate	Homosalate (USP24)
Food red 9	E 123; 3-Hydroxy-4-(4-sulfonato-1-naphthylazo)-naphthalin-2,7-disulfonic acid, Trisodium salt; CAS: 915-67-3
Isopropyl Myristate	Isopropyl Myristate (USPNF19)
Poloxamer 188	Poloxamer 188 (USPNF 19)
Poloxamer 407	Poloxamer 407 (USPNF 19)
paraffin oil, perliquidum	Paraffinum liquidum (Ph. Eur.)
paraffin oil, subliquidum	Mineral oil (USP 24)
Polydimethylsiloxane	Dimethicone (USPNF19)
Potassium hydroxide	Potassium hydroxide (USP24; Reagents)
Quinoline yellow	Type I: 2-(1,3-Dioxo-2-indanyl)-chinolin-disulfonic acid, Disodium salt Type II: 2-(1,3-Dioxo-2-indanyl)-methylchinolin-disulfonic acid, Disodium salt; CAS: 8004-92-0;

17

E 104

Sodium hydroxide	Sodium hydroxide (USPNF19)
Tartrazine	5-Hydroxy-1-(4-sulfonatophenyl)-4-(4-sulfonatophenylazo)-pyrazole-3-carbonic acid, Trisodiumsalt; CAS: 1934-21-0; E 102
Tris(hydroxymethyl)aminomethane	Tromethamine (USP24;Reagents)
Tropaeolin 0	2,4-Dihydroxyazobenzol-4'-sulfonic acid Sodium salt; CAS: 547-57-9
Polysorbate 85	Polyoxyethylene 20 sorbitan trioleate CAS: 9005-70-3
Oxybenzone	Oxybenzone (USP24)
Octyl Methoxycinnamate	Octyl Methoxycinnamate (USP24)
Sulisobenzene	Sulisobenzene (USP24)
2,2',4,4'-tetrahydroxybenzophenone	CAS: 131-55-5
4-Bis(polyethoxy)paraamino-benzoicacid-polyethoxyethylester	CAS: 113010-52-9
2,4,6-trianilino-p-(carbo-2'-ethyl-hexyl-1'-oxi)-1,3,5-triazin	CAS: 88122-99-0
Vanillin	Vanillin (USPNF19)
Vaseline album	Petrolatum (USP24)

CLAIMS

1. A pharmaceutical composition for topical use containing (E)-5-(2-bromovinyl)-2'-deoxyuridine (brivudine) and a photostabilizer selected from
5 the group consisting of carotenoids and derivatives of benzophenon, camphor, cinnamate, diphenyl-propane-1,3-dione, cyano-diphenyl-acrylic acid, phenyl-azo-benzene, together with pharmaceutically acceptable excipients.
2. A pharmaceutical composition according to claim 1, wherein the photostabilizer is selected from the group consisting of carotenoids and
10 derivatives of benzophenone and phenyl-azo-benzene.
3. A pharmaceutical composition according to claim 2, wherein the photostabilizer is an o-hydroxy-benzophenone derivative.
4. A pharmaceutical composition according to claim 3 in which said o-hydroxy-benzophenone derivative is selected from the group consisting of:
15 dioxybenzone, oxybenzone, 2,2',4,4'-tetrahydroxybenzophenone, sulisobenzone, 2,4-dihydroxy benzophenone, 2,2'-dihydroxy-4,4'-dimethoxybenzophenone-5,5'-disodium sulfonate.
5. A pharmaceutical composition according to claim 2, wherein the photostabilizer is a phenyl-azo-benzene-derivative.
- 20 6. A pharmaceutical composition according to claim 5, wherein said phenyl-azo-benzene derivative is selected from the group consisting of 7-Hydroxy-8-(4-sulfonato-1-naphthylazo)-naphthalin-1,3-disulfonic acid trisodium salt, (2,4-dihydroxyazobenzol)-4'-sulfonic acid sodium salt and 3-Hydroxy-4-(4-sulfonato-1-naphthylazo)-naphthalin-2,7-disulfonic acid
25 trisodium salt.
7. A pharmaceutical composition according to claim 2, wherein the photostabilizer is a carotenoid.
8. A pharmaceutical composition according to claim 7, wherein said

carotenoid is beta -carotene

9. A pharmaceutical composition according to any preceding claims, containing at least one photostabilizer.
10. A pharmaceutical composition according to any preceding claims,
5 wherein the concentration of the photostabilizer ranges from 0.1 to 10% w/w.
11. A pharmaceutical composition according to claim 11, wherein said concentration is from 0.5 to 5% w/w.
12. A pharmaceutical composition according to any preceding claims, in the form of tenside gel, microemulsion, hydrogel, O/W cream, W/O cream
10 lipstick, lipogel, ointment.
13. A pharmaceutical composition according to any preceding claims represented by a microemulsion containing: brivudine 1%; oxybenzone 4%; isopropyl myristate 29.5%; poloxamer 101, 11.8%; polysorbate 85, 17.7%; silicon dioxide 10.7%; eventually an antimicrobial preservative; water
15 q.s. ad 100%.
14. A pharmaceutical composition according to any preceding claims, for the topical treatment of varicella zoster virus and herpes simplex type 1 virus infections.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 02/13714

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K31/7072 A61K47/08 A61K47/10 A61K47/12

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, MEDLINE, WPI Data, PAJ, EMBASE, BIOSIS, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 755 675 A (OREAL) 29 January 1997 (1997-01-29) cited in the application page 4, line 31 - line 32 page 5, line 55 - line 57 ---	1-14
Y	FREEMAN D J ET AL: "Preclinical assessment of topical treatments of herpes simplex virus infection: 5% (E)-5-(2-bromovinyl)-2'-deoxyuridine cream." ANTIVIRAL RESEARCH. NETHERLANDS JUN 1985, vol. 5, no. 3, June 1985 (1985-06), pages 169-177, XP008015919 ISSN: 0166-3542 the whole document --- -/--	1-14



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *G* document member of the same patent family

Date of the actual completion of the international search

4 April 2003

Date of mailing of the international search report

11/04/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Boulois, D

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 02/13714

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	DE 199 56 601 A (COGNIS DEUTSCHLAND GMBH) 31 May 2001 (2001-05-31) page 2, line 56 -page 3, line 20 ----	1-14
A	WO 98 10768 A (GLAXO GROUP LTD ;LUDWIG JOHN (US)) 19 March 1998 (1998-03-19) the whole document -----	1-14

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 02/13714

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
EP 0755675	A	29-01-1997	FR 2737118 A1	31-01-1997
			AU 679663 B2	03-07-1997
			AU 5943096 A	13-02-1997
			CA 2182226 A1	29-01-1997
			DE 69600065 D1	23-10-1997
			DE 69600065 T2	08-01-1998
			EP 0755675 A1	29-01-1997
			ES 2109832 T3	16-01-1998
			JP 2965510 B2	18-10-1999
			JP 9040548 A	10-02-1997
			US 6136332 A	24-10-2000
DE 19956601	A	31-05-2001	DE 19956601 A1	31-05-2001
			AU 1394201 A	04-06-2001
			WO 0137798 A1	31-05-2001
WO 9810768	A	19-03-1998	AU 4384297 A	02-04-1998
			WO 9810768 A1	19-03-1998